Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ACADEMIA
ACADEMIA
- Dupixent Used Generally as Adjunctive Therapy to Existing Treatments for Atopic Dermatitis: Dermatologist
May 10, 2018
- 55 Anticancer Meds Available Overseas Unapproved in Japan, 3 Meds Costing over 10 Million Yen Monthly: NCC
May 2, 2018
- New Guidelines Recommend LAMA as First-Line Bronchodilator for COPD: Respiratory Society
April 24, 2018
- Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020
April 23, 2018
- Expert Cautions against Hasty Discussions on Cost Effective Assessments
April 20, 2018
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President
April 19, 2018
- Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
April 19, 2018
- Lynparza Desirable for Use in Early-Stage Maintenance Therapy: Jikei Univ. Prof.
April 2, 2018
- Atherosclerosis Society Issues Statement on Use of PCSK9 Inhibitors, Recommending for Patients with FH, Secondary Prevention in High-Risk Patients
March 6, 2018
- Nephrology Society Compiles New Drug Development Guidelines for Advanced CKD; Will Guidelines for Early-Stage CKD Follow?
March 1, 2018
- LSI Medience, NCC, and NIBIOHN Team Up for National Project to Develop PDX Mice
February 26, 2018
- Major Drug Makers to Join in AMED Project to Develop “Organs on Chips” as New Tools for Drug Discovery
February 22, 2018
- Overseas Meta-Analyses Find Increased Risk of CKD in Patients Who Use PPIs; Japanese Society of Nephrology Plans Study of Japanese Patients
February 2, 2018
- Japan Pediatric Society Launches New Scheme to Promote Development of Pediatric Drugs, Prevent Drug Lag
January 11, 2018
- Japan Dermatological Association Opposes Restrictions on Hirudoid Prescriptions, Warns against Hasty Decision
December 27, 2017
- Neurology Society Revises Epilepsy Treatment Guidelines; Adding Zonisamide as 1st-Line Drug for Partial Onset Seizures
December 12, 2017
- Neurology Society Revises Parkinson’s Disease Treatment Guidelines, Emphasizing L-Dopa-Based Early Treatment
December 12, 2017
- In Renewed Attempt, Tokushima Univ. Starts IIT for Eisai-Dropped ALS Drug Candidate
November 9, 2017
- Japan’s 1st Constipation Treatment Guidelines Recommend Drugs Acting on Epithelial Function Including Amitiza
October 25, 2017
- Nephrology Society to Build Database, Biobank to Support Drug Discovery; Some 20 Companies Interested in Collaboration
October 13, 2017
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…